← Back to Clinical Trials
Recruiting NCT04851886

NCT04851886 PostureCheck: A Vision-based Compensatory-posture-detection Tool for Robot-assisted Upper-limb Therapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04851886
Status Recruiting
Phase
Sponsor Spaulding Rehabilitation Hospital
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 42 participants
Start Date 2024-04-26
Primary Completion 2026-09-30

Trial Parameters

Condition Stroke
Sponsor Spaulding Rehabilitation Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 42
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2024-04-26
Completion 2026-09-30
Interventions
BURTBURT + PostureCheck

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The overall objective of this study is to assess whether robot-assisted upper-limb group rehabilitation can be effectively delivered by using a camera-based system equipped with machine learning algorithms to track the quality of the exercise performance and provide feedback accordingly. To address this question, we plan to carry out a randomized clinical trial to compare outcomes in subjects receiving robot-assisted upper-limb rehabilitation during individual (i.e., one-on-one) sessions and in subjects receiving robot-assisted upper-limb rehabilitation during group (i.e., up to three subjects) sessions.

Eligibility Criteria

Inclusion Criteria: * Have had a history of ischemic cerebrovascular accident (CVA) within middle cerebral artery (MCA) or anterior cerebral artery (ACA) territory * CVA occurred between six months and six years ago * Moderate to severe UE impairment, FMA-UE score between 15 and 45 * Mini-Mental State Examination (MMSE) score \>23 and being able to safely follow three-step commands Exclusion Criteria: * Advanced musculoskeletal pathology or recent fractures in the impaired UE * Previous diagnosis of neurological diseases other than stroke * Severe limitation of passive range of motion or spasticity (Modified Ashworth Scale for spasticity at \<3 for UE muscles) * Hemorrhagic CVA or involvement of the posterior cerebral artery * Aphasia sufficient to limit ability to express needs or discomfort verbally or non-verbally * Impaired visual acuity (Severe visual impairments as assessed by the NIH Stroke Scale Visual Field subscale. (score \>0)) * Severe hemispatial neglect as assessed by the

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology